Form D · Biotechnology
CoapTech, Inc.
Baltimore, MD · CIK 0001823195
Offering snapshot reported Sep 9, 2024 · SEC filing
- Reported sold
- $7.07M Offering amount: $13.5M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 27, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 9, 2024 | Initial | $7,072,474 | No comparison | 6 | SEC filing |
| Jul 31, 2023 | Initial | $4,000,000 | No comparison | 2 | SEC filing |
| Apr 4, 2023 | Initial | $785,000 | No comparison | 1 | SEC filing |
| Sep 4, 2020 | Initial | $7,050,000 | No comparison | 33 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-523479
Source: Form D, filed Sep 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Boyd | Director |
| Howard Carolan | Director, Executive |
| Tim Collins | Director |
| Timothy Collins | Director, Executive |
| Jeffrey Katz | Director |
| William Niland | Director |
| John Osborne | Director |
| Daniel Teo | Director |
| Steven Tropello | Director, Executive |
| William Walker | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 West Dickman Street
Baltimore, MD, 21230
Baltimore, MD, 21230